BRCA1-like signature in triple negative breast cancer: Molecular and clinical characterization reveals subgroups with therapeutic potential
about
Cytotoxic and targeted therapy for hereditary cancersA Comparative Analysis of Genetic and Epigenetic Events of Breast and Ovarian Cancer Related to TumorigenesisPredictors and Modulators of Synthetic Lethality: An Update on PARP Inhibitors and Personalized MedicineOn metabolic reprogramming and tumor biology: A comprehensive survey of metabolism in breast cancerBRCA promoter methylation in sporadic versus BRCA germline mutation-related breast cancers.High Levels of Nucleolar Spindle-Associated Protein and Reduced Levels of BRCA1 Expression Predict Poor Prognosis in Triple-Negative Breast Cancer.Levels of DNA Methylation Vary at CpG Sites across the BRCA1 Promoter, and Differ According to Triple Negative and "BRCA-Like" Status, in Both Blood and Tumour DNA.Next generation sequencing of triple negative breast cancer to find predictors for chemotherapy response.Identification of BRCA1-like triple-negative breast cancers by quantitative multiplex-ligation-dependent probe amplification (MLPA) analysis of BRCA1-associated chromosomal regions: a validation study.Triple negative breast cancer in North of Morocco: clinicopathologic and prognostic featuresNeoadjuvant tamoxifen synchronizes ERα binding and gene expression profiles related to outcome and proliferation.Disease evolution and heterogeneity in bilateral breast cancer.The fate of BRCA1-related germline mutations in triple-negative breast tumors.Germline Mutation Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast Cancer: Secondary Analysis of the GeparSixto Randomized Clinical Trial.Germline Mutations in Triple-Negative Breast Cancer.Exploring phenotype patterns of breast cancer within somatic mutations: a modicum in the intrinsic code.The BRCA1ness signature is associated significantly with response to PARP inhibitor treatment versus control in the I-SPY 2 randomized neoadjuvant setting.NHERF1 together with PARP1 and BRCA1 expression as a new potential biomarker to stratify breast cancer patients.Integrative Analysis with Monte Carlo Cross-Validation Reveals miRNAs Regulating Pathways Cross-Talk in Aggressive Breast Cancer.BRCA1/2-negative hereditary triple-negative breast cancers exhibit BRCAness.
P2860
Q26739366-F307D81D-C0EA-4213-A752-611A482873C0Q26746952-2666F55C-B4E9-4506-8322-F3283A3A0A7DQ28072204-351135E0-4E09-4653-83B2-AA3F06E6BB45Q28072798-E9B9784B-8252-4267-B3BD-2C02D9E3CA4AQ33750060-D3A7822D-1283-44EE-93A1-527AB435C4FCQ35815004-A1C509C6-C0A5-47AD-AC25-031B96B1105EQ36087198-03389C5A-A5F2-4509-9044-CF32D146B059Q36119077-7ECB8854-D7FE-4286-9249-FA1113B0A01DQ36166929-DDC6AD08-152B-4538-9F52-2DE78608D803Q36172054-5F9D0FD9-F49E-407A-ABA6-4A7AD0C3234EQ37376167-F3AF1B0A-A94E-4EDF-A408-A761D3ACB0CEQ37447919-BC56403B-8013-4F5B-96D8-C284E6BC19A7Q37596828-AD72C08D-EE6B-4501-9849-185609FB915EQ38373098-E8C47883-C63F-42EE-83A8-A18ADC6FB676Q39370774-0A2F1CEF-0761-4315-B804-34A3859C3502Q39752527-7FB63BE3-17EE-46AC-8953-6FE70891B01AQ41542872-1D1C7A38-12A0-45FC-8447-2BE0F9E9D311Q42371576-15433860-7FBC-403F-9EC9-027F1CA4E8ABQ42381466-CCF2D89C-201C-4C19-8CB9-7377E3FA78D0Q48906011-F0C30CD9-3B00-4E45-9DBC-0B344BFC049F
P2860
BRCA1-like signature in triple negative breast cancer: Molecular and clinical characterization reveals subgroups with therapeutic potential
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
BRCA1-like signature in triple ...... ups with therapeutic potential
@en
type
label
BRCA1-like signature in triple ...... ups with therapeutic potential
@en
prefLabel
BRCA1-like signature in triple ...... ups with therapeutic potential
@en
P2093
P2860
P50
P1433
P1476
BRCA1-like signature in triple ...... ups with therapeutic potential
@en
P2093
Astrid Bosma
Bernard Pereira
Ian Majewski
Iris M Simon
Jettie J F Muris
Justine Peeters
Lodewyk Wessels
Mae A Goldgraben
Philip C Schouten
Roelof J C Kluin
P2860
P304
P356
10.1016/J.MOLONC.2015.04.011
P577
2015-05-07T00:00:00Z